Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

G1 Therapeutics Inc patents


Recent patent applications related to G1 Therapeutics Inc. G1 Therapeutics Inc is listed as an Agent/Assignee. Note: G1 Therapeutics Inc may have other listings under different names/spellings. We're not affiliated with G1 Therapeutics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | G1 Therapeutics Inc-related inventors


Lactam kinase inhibitors

Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof.. . ... G1 Therapeutics Inc

Highly active anti-neoplastic and anti-proliferative agents

This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.. . ... G1 Therapeutics Inc

Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation

This invention is in the area of tricyclic lactam compounds for and methods of treating selected rb-positive cancers and other rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy hematopoietic stem cells and progenitor cells (hspcs), associated with current treatment modalities. In one aspect, treatment of select rb-positive cancers is disclosed using specific compounds disclosed herein. ... G1 Therapeutics Inc

Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors

This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (rb)-negative cancers and rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (cdk4/6) inhibitors. In one aspect, the improved treatment of select rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase i inhibitor.. ... G1 Therapeutics Inc

Anti-neoplastic combinations and dosing regimens using cdk4/6 inhibitor compounds to treat rb-positive tumors

This invention directed to methods for treating select rb-positive cancers and other rb-positive abnormal cellular proliferative disorders using cdk4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select rb-positive cancers are disclosed using specific cdk4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, pd-1 inhibitor, or bcl-2 inhibitor, or combination thereof.. ... G1 Therapeutics Inc

Transient protection of hematopoietic stem and progenitor cells against ionizing radiation

This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (hspc), from the damage associated with ionizing radiation (ir) exposure using selective radioprotectants.. . ... G1 Therapeutics Inc

Hspc-sparing treatments for rb-positive abnormal cellular proliferation

This invention is in the area of improved compounds for and methods of treating selected rb-positive cancers and other rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy hematopoietic stem cells and progenitor cells (hspcs), associated with current treatment modalities. In one aspect, improved treatment of select rb-positive cancers is disclosed using specific compounds disclosed herein. ... G1 Therapeutics Inc

Transient protection of normal cells during chemotherapy

This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (hspc) as well as renal cells, from damage associated with dna damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (cdk 4/6) inhibitors when administered to subjects undergoing dna damaging chemotherapeutic regimens for the treatment of proliferative disorders.. ... G1 Therapeutics Inc

Lactam kinase inhibitors

Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof.. . ... G1 Therapeutics Inc

Cdk inhibitors

Compounds of formulae i, ii or iii, and pharmaceutically acceptable salts thereof, are useful as cdk inhibitors.. . ... G1 Therapeutics Inc

Transient protection of normal cells during chemotherapy

This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (hspc) as well as renal cells, from damage associated with dna damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (cdk 4/6) inhibitors when administered to subjects undergoing dna damaging chemotherapeutic regimens for the treatment of proliferative disorders.. ... G1 Therapeutics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with G1 Therapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G1 Therapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###